3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Sunitinib
64
Nivolumab
54
Sorafenib
38
Bevacizumab
35
Axitinib
35
pembrolizumab
34
Everolimus
30
cabozantinib
29
pazopanib
26
aldesleukin
26
Ipilimumab
23
Interleukin-2
19
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
Gemcitabine
17
lenvatinib
16
Interferon-alpha
15
Interferon alpha-2
13
Radiosurgery
12
Cyclophosphamide
12
fludarabine phosphate
11
atezolizumab
10
durvalumab
8
Introns
8
Erlotinib Hydrochloride
8
Biopsy
8
temsirolimus
7
avelumab
7
Radiotherapy
7
Capecitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Renal Cell
×
CB-839
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts
NCT03163667
2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2
Completed
69 enrolled
12 charts